Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Clal Biotechnology Industries Ltd. (CBI) operates as a venture capital and private equity firm, primarily funding innovative companies within the life sciences, medical device, biopharmaceutical, and broader biotechnology sectors. The firm is adept at investing across a comprehensive spectrum of development stages, ranging from initial incubation, seed, and startup phases, through early, emerging, mid, and late-stage ventures, including pre-clinical development, PIPEs, and growth capital financing. CBI strategically targets companies based in the United States and Israel, typically deploying between $0.5 million and $10 million into each investment. It frequently assumes the role of a lead investor and a significant shareholder, often securing a board seat within its portfolio companies. Established in July 1998, CBI utilizes the personal capital of its management team for its investments. Its primary base is in Tel Aviv, Israel, complemented by an additional office in Cambridge, Massachusetts. The firm formerly functioned as a subsidiary of Clal Industries and Investments Ltd.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.